MD安德森和BridgeBio制药推出Navire制药制定患者的难以治疗的癌症靶向治疗
MD安德森News Release October 04, 2017
得克萨斯大学MD安德森癌症中心的大学andBridgeBio制药today announced the launch of Navire Pharma, a biopharmaceutical company aimed at developing novel small-molecule inhibitors of a tyrosine-protein phosphatase called SHP2 for genetically driven and treatment-resistant cancer.
BridgeBio已承诺3000万$和一队高级职业经理人的公司，而MD安德森，通过其学院应用科学癌症s（IACS），提供知识产权和肿瘤药物的开发团队走向临床研究进展SHP2抑制剂。
SHP2，由PTPN11基因，链接生长因子信号与下游RAS / ERK / MAPK途径来调节细胞生长和分裂编码。过度活动这一途径的，往往是由不同的基因突变，造成或促成带动许多人类癌症。抑制SHP2提供了一种新的方法来治疗肿瘤依靠这一途径。
Shafique Virani, M.D., joins BridgeBio as CEO in residence, and will serve as CEO of Navire. Virani was most recently officer and vice president of Business Development, Licensing, and M&A at Roche/Genentech where he assumed several leadership roles across the globe over 13 years.
“Navire的化合物强烈结合SHP2和防止蛋白质的活化，阻断其促进肿瘤生长的能力，” Virani说。“直接抑制SHP2可能患者和医生提供一种新的，变革性的做法从源头治疗RTK导致的癌症。”
Navire Pharma’s lead compounds were discovered and developed by the IACS team led by Phil Jones, Ph.D., executive director and head of drug discovery at IACS, together with Benjamin G. Neel, M.D., Ph.D., director of the Laura and Isaac Perlmutter Cancer Center at New York University (NYU).
“导致许多患者停止响应治疗耐药机制依赖于SHP2活动，”琼斯，Navire的科学的创始人之一说。“我们的‘分子胶水’抑制方法灭活SHP2和可以帮助克服这些阻力的途径。”
SHP2 also suppresses T-cell activity against growing tumors through regulation of the adaptive immune response by binding to PD-1 and dephosphorylating CD28 and the protein LCK. SHP2 inhibition may relieve this negative effect, enhancing the patient’s immune response to fight cancer proliferation.
“SHP2’s role in oncogenic signaling has been known for decades, but effective approaches for inhibiting the protein were only recently discovered,” said Neel, Navire scientific co-founder and chairman of the company’s scientific advisory board. “These novel approaches have demonstrated compelling efficacy in pre-clinical disease models, which we hope will translate into benefit for patients.”
Navire的科学顾问委员会的其他成员，包括在细胞信号传导和血液和实体肿瘤的领导人，包括：
- Kwok Kin-Wong, M.D., Ph.D., chief of Hematology and Medical Oncology, NYU
- Scott Kopetz, M.D., Ph.D., associate professor, Gastrointestinal Medical Oncology, MD Anderson;
- Frank McCormick, Ph.D., director of the University of California, San Francisco (UCSF) Cancer Center and associate dean of the UCSF School of Medicine, and co-founder, Onyx Pharmaceuticals;
- Lillian Siu, M.D., professor of Medicine, Princess Margaret Cancer Centre, Toronto.
BridgeBio还增加了制药和生物技术管理人员到Navire团队，包括乌玛·辛哈博士和布赖恩·梅特卡夫博士，谁共同拥有先进的30多个候选药物进入人体试验，并带来了9安全有效的药物产品推向市场。该BridgeBio团队将通过密切IND申报与MD安德森合作，并起诉随后的临床试验。
“Navire结合MD安德森的医生和药物开发的科学家与我们的老生物技术团队创建一个集中的组织，开发SHP2靶向治疗”，尼尔·库马尔博士，BridgeBio药业的首席执行官。“总之，我们的目标是尽快的机会，使这些新的治疗方法给患者。”